GoAI
Get started
Exicure, Inc. logo

Exicure, Inc.

XCUR

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$1.15

−$0.15 · -11.54%

Aug 21, 4:00 PM ET

XCUR company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Strong Sell

Exit — multiple negative signals converging

Valuation

20

Overpriced

Momentum

21

Weakening

Sentiment

41

Mixed

Risk resilience

2

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Exicure, Inc. is a biotechnology firm that utilizes its unique spherical nucleic acid (SNA) platform to create therapies for neurological conditions and hair loss. Its primary experimental candidate, SCN9A, is currently undergoing preclinical evaluation for addressing neuropathic and chronic pain. The company has entered into a strategic partnership with AbbVie Inc. to advance SNA-based solutions for various hair loss conditions, under a collaboration, option, and license agreement. Additionally, a separate collaborative effort with Ipsen S.A. aims to investigate, develop, and commercialize novel spherical nucleic acids targeting Huntington's disease and Angelman syndrome. Established in 2011, Exicure's corporate base is located in Chicago, Illinois.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Jungsoo Kim
Listed since
May 22, 2018
Employees
8

Market position

Day range

Current $1.15

52-week range

Current $1.15

Open
$1.32
Previous close
$1.30
Volume
150.79K
0.37× average
Average volume
402.53K
Average daily volume
Market cap
7.33M USD
Beta
3.66
Market reference 1
50-day average
$1.8381
-37.44% below average
200-day average
$3.6869
-68.81% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
30.56M USD
EV / EBITDA
-5.97×
Earnings yield
-14.49%
Free cash flow yield
-25.07%

Profitability & efficiency

Return on equity
-125.98%
Return on assets
-35.23%
Return on invested capital
-86.82%

Financial health

Current ratio
1.19×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends14843%8556%2269%-4018%Gross margin, FY2021: 100.00%Gross margin, FY2022: 93.56%Gross margin, FY2024: 100.00%Operating margin, FY2021: 12950.10%Operating margin, FY2022: -6.35%Operating margin, FY2024: -2446.40%Net margin, FY2021: 13271.64%Net margin, FY2022: -8.96%Net margin, FY2024: -1940.20%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 93.56%. Gross margin FY2024 100.00%. Operating margin FY2021 12950.10%. Operating margin FY2022 -6.35%. Operating margin FY2024 -2446.40%. Net margin FY2021 13271.64%. Net margin FY2022 -8.96%. Net margin FY2024 -1940.20%.

Income trends

Revenue

500K USD-98.27%

Operating income

−10.12M USD+17.29%

Net income

−4.95M USD+49.02%
Income trends across reported periods38.12M USD947.6K USD−36.22M USD−73.39M USDRevenue, FY2021: −483K USDRevenue, FY2022: 28.83M USDRevenue, FY2024: 500K USDOperating income, FY2021: −62.55M USDOperating income, FY2022: −1.83M USDOperating income, FY2023: −15M USDOperating income, FY2024: −12.23M USDOperating income, FY2025: −10.12M USDNet income, FY2021: −64.1M USDNet income, FY2022: −2.58M USDNet income, FY2023: −16.91M USDNet income, FY2024: −9.7M USDNet income, FY2025: −4.95M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 −483K USD. Revenue FY2022 28.83M USD. Revenue FY2024 500K USD. Operating income FY2021 −62.55M USD. Operating income FY2022 −1.83M USD. Operating income FY2023 −15M USD. Operating income FY2024 −12.23M USD. Operating income FY2025 −10.12M USD. Net income FY2021 −64.1M USD. Net income FY2022 −2.58M USD. Net income FY2023 −16.91M USD. Net income FY2024 −9.7M USD. Net income FY2025 −4.95M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue—500K USD—28.83M USD−483K USD
Cost of goods sold460K USD—1.42M USD1.86M USD—
Gross profit−460K USD500K USD−1.42M USD26.97M USD−483K USD
Research and development3.29M USD—1.42M USD19.77M USD48.98M USD
Selling, general, and administrative6.83M USD5.45M USD12.65M USD10.89M USD13.09M USD
Operating expenses9.66M USD12.73M USD13.57M USD28.8M USD62.07M USD
Interest income29K USD8K USD32K USD15K USD141K USD
Interest expense1K USD18K USD—595K USD1.69M USD
Depreciation and amortization460K USD824K USD1.38M USD1.86M USD1.78M USD
Operating income−10.12M USD−12.23M USD−15M USD−1.83M USD−62.55M USD
Net income−4.95M USD−9.7M USD−16.91M USD−2.58M USD−64.1M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 2 misses, 0 met estimates
Average EPS surprise
+54.18%
11 comparable reports
Latest EPS result
-0.18
Estimate -18.6 · Beat by 99.03%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.15-8.2-16.24-24.29Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 18, 2025: actual -22.5, estimate -21, surprise -7.14%, Miss. Q2 2025, reported Jun 27, 2025: actual -0.45, estimate -10.5, surprise +95.71%, Beat. Q3 2025, reported Aug 8, 2025: actual -0.41, estimate -6, surprise +93.17%, Beat. Q4 2025, reported Nov 7, 2025: actual -0.39, estimate -4.5, surprise +91.33%, Beat. Q1 2026, reported Mar 25, 2026: actual -0.46, estimate -0.95, surprise +51.58%, Beat. Q2 2026, reported May 29, 2026: actual -0.29, estimate -0.95, surprise +69.47%, Beat. Q3 2026, reported Aug 14, 2026: actual -0.18, estimate -18.6, surprise +99.03%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate -21, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates23.39M16.03M8.68M1.32MQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26EstimateQ3 '26EstimateQ4 '26Estimate
Q1 2025, reported Mar 18, 2025: actual 2.12M USD, estimate 3.5M USD, surprise -39.51%, Miss. Q2 2025, reported Jun 27, 2025: actual 2.57M USD, estimate 4.3M USD, surprise -40.35%, Miss. Q3 2025, reported Aug 8, 2025: actual 2.47M USD, estimate 4.1M USD, surprise -39.73%, Miss. Q4 2025, reported Nov 7, 2025: actual 2.02M USD, estimate 3.9M USD, surprise -48.31%, Miss. Q1 2026, reported Mar 25, 2026: actual 21.77M USD, estimate 3.9M USD, surprise +458.31%, Beat. Q2 2026, reported May 29, 2026: actual —, estimate 3.9M USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 14, 2026: actual —, estimate 1.64M USD, surprise —, Comparison unavailable. Q4 2026, reported Nov 12, 2026: actual —, estimate 1.55M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

6 ratings
Strong buy00%
Buy583%
Hold117%
Sell00%
Strong sell00%

XCUR news

globenewswire.com

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (“GPCR…

Read source
globenewswire.com

Exicure Announces Board and Committee Changes

WILMINGTON, Del., June 30, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) ("Exicure" or the "Company") today announced changes to its Board of Directors and Board committees following actions approved by the…

Read source
globenewswire.com

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement

WILMINGTON, Del. , June 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (the "Company") today announced that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock…

Read source
globenewswire.com

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

WILMINGTON, Del., June 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (the “Company”) today announced that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock…

Read source
globenewswire.com

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

Exicure announced receipt of a Nasdaq notice related to the delayed filing of its Form 10-Q and confirmed that the Form 10-Q was filed on May 29, 2026.

Read source

Corporate actions

Corporate action history

Stock split

Effective Aug 28, 2024

1:5

Stock split

Effective Jun 30, 2022

1:30

XCUR peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding XCUR

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
46.21K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
22.76K
Weight
—
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%

Continue in GoAI

Research XCUR

research.disclaimer